The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase III trial of second-line chemotherapy comparing CPT-11 alone versus S-1 plus CPT-11 combination therapy in advanced gastric cancer refractory to first-line therapy with S-1 (JACCRO GC-05).
Kazuhiro Nishikawa
No relevant relationships to disclose
Kazuaki Tanabe
No relevant relationships to disclose
Masashi Fujii
Consultant or Advisory Role - Taiho Pharmaceutical
Stock Ownership - Eisai (I); Takeda (I)
Honoraria - Sanofi ; Taiho Pharmaceutical
Chikara Kunisaki
No relevant relationships to disclose
Akihito Tsuji
Honoraria - Taiho Pharmaceutical; Yakult
Nobuhisa Matsuhashi
No relevant relationships to disclose
Akinori Takagane
No relevant relationships to disclose
Tetsuro Ohno
No relevant relationships to disclose
Tomono Kawase
No relevant relationships to disclose
Mitsugu Kochi
Honoraria - Taiho Pharmaceutical
Kazuhiro Yoshida
Honoraria - Daiichi Sankyo; Taiho Pharmaceutical; Yakult
Research Funding - Daiichi Sankyo; Taiho Pharmaceutical; Yakult
Yoshihiro Kakeji
Honoraria - Taiho Pharmaceutical
Wataru Ichikawa
Honoraria - Daiichi Sankyo; Taiho Pharmaceutical; Yakult
Keisho Chin
No relevant relationships to disclose
Masanori Terashima
No relevant relationships to disclose
Masahiro Takeuchi
Consultant or Advisory Role - Taiho Pharmaceutical
Toshifusa Nakajima
No relevant relationships to disclose